Medtronic received European regulatory approval for its Viva cardiac resynchronization therapy-pacemaker (CRT-P).
The device features Medtronic’s AdaptivCRT algorithms that continuously adjust the output signal of the device to improve response to the therapy and help minimize cases of atrial fibrillation.
From the announcement:
Independent studies have validated the benefits of the algorithm, including:
- AdaptivCRT increases CRT response rate by 12 percent;
- Patients with AdaptivCRT have a demonstrated 21 percent reduction in heart failure hospitalization and a reduced risk of death;
- Patients with AdaptivCRT have a 46 percent reduced risk of AF2.
- Viva CRT-P also features advanced diagnostics tools, such as OptiVol® Fluid Status Monitoring and Cardiac Compass® Report, which provide unmatched levels of insight into patients’ physiological condition. These tools are proven to identify patients at risk for rehospitalization within 30 days of discharge, a critical quality measure.